Objective: We aimed to estimate the effective dose of 4D-Perfusion-CT protocols of the lung, liver, and pelvis for the assessment of tumor vascularity.
erfusion CT was introduced several years ago as an adjunct to morphological imaging in tumor patients. Considering tumor perfusion as an in vivo marker of angiogenesis, the first studies showed reliable results for diagnosis, risk-stratification, and therapy monitoring of several tumor entities (1) . This functional imaging technique has emerged as a new tool in the evaluation of blood supply and perfusion characteristics in the oncological field. For example, in colorectal cancer, the second most common cancer in the western world, the main mechanism activating neovascularization is angiogenesis, which is the growth of new blood vessels. Neovascularization arises early via the upregulation of several angiogenetic factors. Thus, the assessment of the tumor microvascularity by perfusion CT could play an important role in the management of oncologic patients (2) . The first clinical trials suggest that merely using tumor size is not sufficient for monitoring modern antiangiogenesis drugs. In contrast, the functional information of perfusion CT could be used to monitor anti-angiogenesis therapy, which is increasingly used in oncologic therapy (1, 3) .
The introduction of a new 128-slice single source scanner technique allows for oncologic perfusion imaging with its inherent possibility of 4D spiral scanning. This is implemented by bidirectional table movements and broad detector range, resulting in coverage of organs and tumors up to a craniocaudal extent of 96 mm. On the other hand, modern tube techniques allow constant image quality over a time period of 120 seconds. However, in younger oncologic patients, the radiation exposure originating from additional spiral scans for tumor diagnosis or follow-up has to be considered. To the best of the authors' knowledge, no recent data is available, regarding the evaluation of effective whole-body and organ specific doses of 4D spiral scanning using a single source 128-slice scanner.
The aim of this study was to estimate gender specific effective whole-body and organ-specific doses when using 4D perfusion protocols for the lung, liver, and pelvis in normal-weighted and obese patients. The experimental dose measurements may lend support for consideration of new dose-balanced anatomo-functional CT imaging protocols that are dose neutral with existing oncologic CT investigational protocols.
MATERIALS AND METHODS

Dosimetry
Dose measurements were performed using an anthropomorphic phantom (Alderson-Rando-Phantom; Alderson Research Laboratories Inc., Stanford, CT) equipped with 117 thermoluminescent dosimeters (TLDs) measuring 1 × 1 × 6 mm (TLD-100H, Bicon-Harshow, Radiation Measurement Products, Cleveland, OH) ( Fig. 1) (4-6) .
Thirty-nine different positions in the Alderson-RandoPhantom corresponding to the anatomical position of each individual organ were used for determining organ dose.
Three TLDs were placed at each point of dose measurement to minimize bias due to measurement deviation. The number of TLDs allocated to different organ position were as follows: three at the brain, thyroid gland, esophagus, thymus, heart, breast, stomach, upper colon, spleen, kidneys, adrenal glands, pancreas, small intestine, lower colon, urinary bladder, muscle tissue, red bone marrow, skin, ovaries and testicles, 42 at the lung, and 15 at the liver. In organs which exist in pairs, the TLDs were positioned on the right side.
The evaluation of the irradiated TLDs (within 24 hour after exposure) was performed using a TLD reader (Model 5500 TLD Reader, Bicron Radiation Measurement Products, Solon, OH). The readout TLD values in nanocoulombs were multiplied by an individual calibration factor, which was defined by the means of parallel exposure in 33 TLDs, multiplied by a known radiation dose using 100 kV and 80 mA for 100 ms at an SSD of 100 cm (Elektra PreciseSim X-ray simulator, Stockholm, Sweden). To minimize the heel effect, wire markers in the field were avoided and all exposures were administered in the same position with respect to the orientation of the Xray tube. The reference TLDs were exposed with a dose of 1.055 mGy and crosschecked by an ionization dosimeter positioned at the same phantom depths. No further correction factors were used since the calibration voltage was close to the CT's tube voltage (4) .
The effective dose was calculated according to the guidelines of International Commission on Radiological Protection (ICRP) 103 by summarizing the weighted organ doses (7); the radiation dose of simulated small organs (i.e., thyroid gland) were directly rated into the calculation 
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(mean of measured TLDs). Doses for larger organs (i.e., lung) were determined by determining the mean of measured TLDs from the entire organ.
To assess gender-specific differences, the testicles were used to measure the male-specific gonad dose while radiation dose of the breast and ovaries accounted for the female-specific radiation exposure.
Scan Protocols
For all CT examinations, a 128-slice single source scanner was used (SOMATOM Definition AS+, Siemens Medical Solutions, Forchheim, Germany). Data acquisition was performed in the supine position using a topogram to determine the examination scan range. Scans of three different organ regions were measured: one protocol was centered at the pulmonary hilum, one at the liver, and one at the pelvic inlet. To date, no consensus of the perfusion CT protocols has emerged (1). Therefore, the following protocols for normal weight (body mass index < 30 kg/m Table 1 . For the 4D scanning mode, repeated 3D scans were used to monitor both the first pass and subsequent phases of tumor perfusion, which was determined by the contrast material in the intravascular and extravascular compartments (1, 2, 14) : first phase, 10 scans every 2 seconds, second phase, 10 scans every 3 seconds and third phase, 6 scans every 10 seconds beginning after a start delay of 5, 7 and 9 seconds after contrast media application (50 ml) for the lung, liver, and pelvis perfusion, respectively.
For the first phase, body perfusion software (Siemens Medical Solutions, Forchheim, Germany) uses the onecompartment method to analyze the perfusion images during the first pass to calculate blood flow, expressed in a unit of ml/100 ml/min. In the interstitial phase, the blood volume (ml/100 ml) is calculated by the two-compartment or Patlak's method to measure the blood flowing in the tissue. Permeability (ml/100 ml/min) is analyzed by the transit constant (K trans ) using Patlak's method and measured the fraction of contrast media at the end of the arterial capillaries in relation to the potential to diffuse into the extravascular and extracellular space respectively (11) .
To avoid unnecessary X-ray radiation remote of the clinically relevant area being scanned, the so called zoverscanning, a new adaptive dose shield technique was performed in this 128-slice scanner for all scan protocols.
RESULTS
Effective gender-specific dose perfusion protocols of the pulmonary hilum, liver, and the pelvic inlet are displayed in Table 2 .
Using the lung perfusion protocol, organs within the range of the primary beam received effective organ doses of up to 3.0 mSv (breast tissue) or 2.9 mSv (lung tissue), respectively. In the liver perfusion protocol, significant doses were evident in liver tissue (1.1 mSv/1.5 mSv) and stomach (3.1 mSv/6.4 mSv) for normal weighted and obese patients. For the pelvic perfusion, significant organ doses were observed, especially in the region of the ovaries (3.0 mSv/6.1 mSv) and the urinary bladder (1.5 mSv/3.1 mSv) for the 80 and 120 mAs protocols.
The radiation dose applied to gender-specific organs such as the breast using the lung perfusion protocol or the ovaries in the pelvic perfusion protocol are responsible for the increase of the radiation dose in females (up to 86% or 100%) in both protocols (normal weight patients), respectively. Due to the lack of gender-specific organs in the scan range of the liver perfusion, the effective doses of males and females are comparable (Fig. 2) for normal weighted and obese patients (Table 3 ). An increase in the tube current from 80 to 120 mAs was noted in protocols for obese patients led to a higher radiation dose (up to 109%) in females for the pelvic perfusion protocol.
DISCUSSION
Since it was demonstrated for several tumor entities that high values of tumor microvessel density and high vascular endothelial growth factor expression are associated with poor outcomes, the use of perfusion CT as an in vivo marker for angiogenesis has emerged as a promising tool for tumor diagnosis and therapy monitoring, especially due to the high reproducibility of quantitative perfusion imaging (15) (16) (17) (18) (19) (20) .
As no larger clinical trials evaluated the value of perfusion CT up to today, no standard protocols are available. Therefore, perfusion CT is usually performed as an add-on to the standard oncological whole-body scans for diagnosis, risk stratification, and therapy monitoring (2, 14, 15) .
The radiation dose of additional CT scans is a cause of concern, especially in younger oncologic patients, due to the associated risk of developing secondary malignancies (21) .
Due to the updated ICRP 103 tissue weighting factors, recent conversion coefficients based on ICRP 60, underestimate the effective dose compared to organ-dose-based calculations. Christner et al. (22) reported a 7% decrease in effective dose for CT examinations of the abdomen and pelvis, but did note an increased estimated effective dose of 4% and 14% for scans of the liver and chest, respectively, compared to the ICRP 60 based conversion coefficients. Furthermore, the updated weighting factor for the female breast (0.05 to 0.12) leads to an increased femalespecific effective dose for thoracic examinations up to 31%, compared to ICRP 60 (23) .
Depending on gender and the evaluated body region and protocols for normal weight or obese patients, an effective whole-body dose between 2.9 and 12.2 mSv was measured. Our data show an increase in effective radiation exposure in the area of respective scan range, whereas the additional radiation dose is relatively low outside of the scan range. In perfusion protocols of the lung, the female effective dose increases by 86% (normal weighted patients) due to the radiation sensitive breast tissue located in the range of primary beam. Therefore, for younger women especially, the potential adverse effects regarding the life-time risk for breast cancer have to be considered. The measured perfusion of the pelvic inlet also showed an increase in female specific radiation dose by 100% (normal weighted patients) due to the ovarian tissue in the scan range. The highest measured effective whole body dose was observed performing a liver perfusion scan because of the stomach mucosa situated in the scan range. However, no gender-specific differences were evident in these cases. The above mentioned gender-and organ-specific differences have to be considered in indicating and planning perfusion CT imaging.
Another aspect that has to be further evaluated in upcoming larger clinical trials are the specific optimization of scan parameters (i.e., tube current and tube potential for normal weighted and obese patients) in order to keep the radiation exposure as low as reasonably achievable, while providing reliable information about perfusion parameters such as organ or tumor blood flow, blood volume, mean transit time, and vascular permeability (24, 25) . In this trial, the effective whole-body dose increases in the pelvic perfusion protocol for obese females by up to 109% in the 120 mAs protocol compared to the 80 mAs perfusion scan.
In the present study, tube current and tube potential was chosen according to the first clinical experiences in our institution. It has to be considered that radiation dose increases linearly with tube current. In contrast, tube potential changes cause a substantial change in radiation dose, which is proportional to the square root of the tube voltage (26) .
Since radiation exposure also shows a linear dependence on the scan range, the possible scan range of 69 to 96 mm for 4D perfusion scanning has to be chosen responsibly and based on clinical relevance by an experienced radiologist (27) . Other possibilities to control radiation exposure are to reduce the number of perfusion scans in order to reliably characterize the tissue response curve, which also has to be evaluated in further clinical trials.
In conclusion, the significant additional radiation exposure inherent with 4D perfusion scanning must be carefully weighed against the benefit of additional functional information, and demands a responsible use of this promising new technique. In particular, the development of combined dose-balanced anatomo-functional CT investigational protocols should gain priority, as the evaluation of response to treatment using perfusion measurements makes additional helicals (e.g., portalvenous, equilibrium phase) obsolete. Furthermore, the general clinical context (e.g., curative vs. palliative chemotherapy) is decisive for the appreciation of long term cancerous complications of increased CT-radiation exposure. Moreover, the evaluation of novel emerging antiangiogenic therapies makes perfusion measurements mandatory and one should keep in mind that CT is and will still remain the mainstay in the imaging diagnosis of oncologic patients and that adapted one-stop shop protocols combining whole-body screening in Care-dose technique and tumor focused perfusion data acquisition could represent a future solution for a more accurate evaluation of cancer patients.
